Treatment Of Cough In Children Research Articles

ВОЗМОЖНОСТИ ТЕРАПИИ КАШЛЯ У ДЕТЕЙ

Acute respiratory infections (ARI) are the main reason for morbidity in childhood. In ca. 90% of cases, they are accompanied by cough. The purpose of this research was to study the effectiveness and safety of the STODAL® drug in the treatment of cough in children. Materials and methods used: a multicenter prospective observational non-randomized clinical study was conducted involving 1000 outpatients with ARI aged 2 to 7 y/o and whose cough duration did not exceed 3 days from the onset of the disease. All of them were prescribed and treated with the complex homeopathic anticough drug on the day of their visit to pediatric practitioner in the outpatient hospital facilities. The patients were divided into two age groups as follows: G1 (n=500) of children aged 2 to 4 y/o and G2 (n=500) of children aged 4 years and 1 day old to 7 y/o. Results: on the 7th day of the therapy, a statistically significant decrease in the severity of daytime cough was noted: in G1 the severity of cough decreased by 1.51 points (from 2.16 to 0.65 points, p<0.001) and by 1.56 points (from 2.24 to 0.68 points, p<0.001) in G2. There was no difference in the reduction in daytime cough severity between the groups (p=0.158). The severity of night cough in G1 decreased by 1.16 points (from 1.64 to 0.48 points, p<0.001) and by 1.25 points (from 1.71 to 0.46 points, p<0.001) in G2. There were no differences in the dynamics of the severity of night cough between the groups as well (p=0.135). The proportion of patients whose cough resolved completely or became clinically insignificant on the 7th day of treatment was 98%, these patients were therefore considered recovered. Cough treatment was rated positively by 95.1% of parents/caretakers. Adverse events (AEs) were reported in 5 patients (0.5% of all cases) and there were no serious AEs among them. Conclusion: the effectiveness and safety of the STODAL® drug in the treatment of cough in ARI in children aged 2 to 7 y/o allows recommending a homeopathic drug with complex anti-inflammatory, antitussive and antimicrobial action for its inclusion in the treatment regimens starting from the first days of the disease.

Clinical Analysis of Painless Micro Acupuncture in Treatment of Cough in Children

Clinical Analysis of Painless Micro Acupuncture in Treatment of Cough in Children

Symptomatic treatment of cough in children

Cough is one of the most common symptoms in paediatric practice. Cough nature, duration, intensity, frequency, time and cause of occurrence should be considered in the differential diagnosis of its causes. Sputum evacuation disorders and changes in its rheological properties are indications for the prescription of mucoactive drugs. Despite the fact that the drugs included in this group have different mechanisms of action, all of them restore mucociliary clearance and lead to effective evacuation of secretions from the respiratory tract. Herbal medicinal products can be used along with classic mucoactive drugs (mucolytics, mucopegulators and mucokinetics). Ivy leaves are an example of a well-known and meticulously researched source of phytopharmaceutical products, they are included in the ESCOP monograph and entered into the positive list of the German Commission E. The efficacy and safety of ivy leaf products have been demonstrated in various controlled clinical studies. The authors presented a review of published clinical studies and non-interventional studies involving a total of 65,383 patients suffering from both acute and chronic respiratory diseases. The studies demonstrated the efficacy of ivy leaf extract preparations as achievement of a higher level of bronchodilation and surfactant production, which led to bronchospasmolytic, secretolytic, expectorant and, in turn, antitussive action. Herbal medicinal products are now actively used in the treatment of new coronavirus infection. Hedelix is one of the ivy leaf extract pharmaceutical preparations approved for use in children over the age of two years.

Therapeutic efficacy and tolerability of syrup based on natural active ingredients in the treatment of cough in children with an acute respiratory infection

Introduction. Acute respiratory infections occupy the leading place in the structure of total infectious morbidity and account for more than 90% of all cases of infection. One of the most frequent clinical symptoms of acute respiratory infections is cough.Aim. To evaluate the therapeutic efficacy and tolerability of syrup based on active natural components in the treatment of cough in 2 to 7 years old children.Materials and methods. Patients 2 to 7 years old diagnosed with mild to moderate acute respiratory infections who had been coughing for no more than 3 days were included in the study.Results and discussion. We observed 123 children: 67 boys (54.5%) and 56 girls (45.5%). A statistically significant reduction in the severity of cough occurred on the 3rd day of treatment in both groups. On the 7th day of treatment, the degree of cough severity in both groups decreased on an average of 5 times. By the 7th day of taking the syrup, 97% of the children showed positive therapeutic effect: 55% of the patients’ cough symptoms resolved completely, 43% of the children had cough symptoms that became clinically insignificant. All these children recovered and were allowed to attend educational institutions. Reduction in the severity of cough when taking a syrup based on natural active components was accompanied by normalization of night sleep on average on the 4th day from the start of treatment.Conclusion. Receiving a syrup based on natural active ingredients in the early administration (within 3 days of coughing) for acute respiratory infections of mild and moderate severity allows 97% of children to cure a cough within 7 days.

The role of herbal medicines in treating cough in children

The physiological role of cough is to restore mucociliary clearance in the respiratory tract. However, if there are inflammatory changes against the background of a respiratory infection, cough may be non-productive and impair the patient’s quality of life. For a rational choice of drug, the true cause of cough should be determined on the basis of history, physical examination and, if necessary, additional instrumental/laboratory investigations. Modern phytopharmaceuticals are considered effective and safe for cough relief. Herbal medicines contain biologically active substances, which are incorporated into the metabolic processes of the body in a more natural way, in contrast to synthetic analogues. The article focuses on the effectiveness of an ivy leaf extract, which has a complex composition: it contains saponins, flavonoids, glycosides, as well as components of essential oils. Due to its composition, it has several effects: expectorant due to its secretolytic and mucolytic action, and antispasmodic based on the increased sensitivity of β2-adrenoreceptor cells of bronchial smooth muscle cells to endogenous and exogenous stimulation, on reducing intracellular calcium levels and bronchial relaxation. The efficacy of ivy leaf extract has been shown in a total of more than 20 clinical trials, mainly in children suffering from upper respiratory tract infections. Cough treatment aims at changing the rheological properties of the secretion and increasing the effectiveness of the cough. The good compatibility of herbal medicines with other drugs, including antibiotics, allows their use not only as monotherapeutic agents, but also in combination therapy for the treatment of cough in children.

Non-prescription antibiotic use for cough among Chinese children under 5 years of age: a community-based cross-sectional study

ObjectiveThis study aimed to investigate the non-prescription use of antibiotics for cough among children under 5 years in China.DesignA community-based cross-sectional survey.SettingA face-to-face interview based on a standard questionnaire in...

Efficacy of a Medical Device Based on Plant Extracts for the Symptomatic Treatment of Cough in Children and Adults. A Clinical Study

Efficacy of a Medical Device Based on Plant Extracts for the Symptomatic Treatment of Cough in Children and Adults. A Clinical Study

Efficacy and safety of the syrup \u201cKalobaTUSS\xae\u201d as a treatment for cough in children: a randomized, double blind, placebo-controlled clinical trial

BackgroundAcute cough in children often causes discomfort to children and parents, reducing their quality of life. Despite the extensive utilization of over-the-counter remedies for cough, the efficacy of most of these treatments in children has not been confirmed.MethodsWe conducted a randomized, double blind, placebo-controlled clinical trial of 106 children with acute cough to evaluate the efficacy and safety of KalobaTUSS®, a paediatric cough syrup based on acacia honey and on Malva sylvestris extract, Inula helenium extract, Plantago major extract, and Helichrysum stoechas extract by using a validated 6 points Likert scale.ResultsChildren were orally treated with KalobaTUSS® or placebo for 8 days. Children receiving KalobaTUSS® showed an early and significant reduction in night-time and day-time cough scores measured using a specific scale and a shorter duration of cough than children treated with the placebo.ConclusionsKalobaTUSS® is well tolerated and produces positive effects by reducing the severity and shortening the duration of cough in children.Trial registrationClinicaltrials.gov no. NCT04073251. Retrospectively registered.

Approaches to the treatment of cough in children

Acute respiratory infections (ORI) are one of the most common causes of primary medical care in Pediatrics. The clinical picture of ORI is almost always accompanied by a combination of symptoms such as nasal discharge, nasal congestion, sore throat and cough, combined with muscle pain, weakness, fatigue, headache, and decreased appetite. Depending on the pathogen of the disease, there is a predominance of one of the symptoms and, therefore, the clinical picture of ORI can be very diverse and is determined by the anatomical localization of the main manifestations of infection. Cough is the most common symptom of acute respiratory diseases in children and is a protective reflex aimed at clearing the Airways in conditions of insufficient mucociliary clearance. By evaluating certain characteristics of a cough, pediatricians can determine the location and often the nature of the disease that causes it. By nature, it can be productive and unproductive (depending on the presence of sputum), by duration acute, subacute and chronic. The main causes of coughing in children are inflammation of the upper and lower respiratory tract, bronchial asthma, and foreign bodies in the bronchi. and timely diagnosis of the disease. Treatment of asthma, bronchiolitis, whooping cough, pneumonia, aspiration of foreign bodies. the Effectiveness of cough therapy depends on the timely and correct determination of the cause that causes it. Therapy should be aimed at thinning sputum, reducing the viscosity and increasing the productivity of the cough. As an antitussive agent, the use of ivy leaf syrup Gedelix is justified. The safety of the drug and the possibility of accurate dosing justify its use in Pediatrics.

Рациональный подход к лечению кашля у детей

Рациональный подход к лечению кашля у детей

Efficacy, Safety and Palatability of the Syrup "KalobaTuss® Children" for the Treatment of Cough in Children

Efficacy, Safety and Palatability of the Syrup "KalobaTuss® Children" for the Treatment of Cough in Children

The herbal preparations in the treatment of cough in children with respiratory infections

Acute respiratory infections (ARI, commen cold) are the most common infection diseases in children. They account for up 75% of all cases of respiratory diseases. In most cases, ARI are selfterminating diseases that require only symptomatic treatment. The most common symptom of ARI is cough. In outpatient practice justified the use of herbal medicine. As an antisussive well eastablished syrup Gedelix. The effectivnesses of the medicine, the possibility of accuracy dosing, pleasant taste facilitate it use in children.

Спорные и нерешенные вопросы в терапии кашля у детей в амбулаторной практике

Спорные и нерешенные вопросы в терапии кашля у детей в амбулаторной практике

Diagnosis and treatment of cough in children

Cough is one of the most common reasons for seeking medical care and may be one of the manifestations of the respiratory tract pathology and various extrapulmonary diseases. Given the diversity of causes of cough, the individualized approach to differential diagnosis and rational purpose of antitussive therapy is required. Agents of plant origin used in the treatment of cough, differ in composition, mechanism of action, forms of production; their modern production must be accompanied by strict control of collection, storage and processing of raw materials. The syrup Eucabal has an expectorant, anti-inflammatory, antioxidant and bactericidal activity by increasing the activity of ciliated epithelium of the mucous membranes of the respiratory tract, reducing hypersecretion, liquefying the phlegm and accelerating its evacuation.

Рациональная муколитическая терапия кашля у детей

In a review article is presented the modern understanding of the main causes of the formation and etiopathogenic approaches to the treatment of cough in children; the action of drugs used in pediatric practice is described. Key words: cough, children, theatment.

Treatment of cough in children with ARVI

Treatment of cough in children with ARVI

Cough in Children: Clinical Approach

Cough is an important reflex defense mechanism and it cleans the airways with the various stimuli. Children are more sensitive than adults to these environmental stimuli. Full mechanism of the cough reflex have not been completely analyzed. Causes of chronic cough in children are different from adults. Even cough is normal for most children, the presence of cough may be indicative of serious disorders and should be considered important because cough affects the child’s quality of life. All children with chronic cough should be evaluated for diagnosis. Cough in children should be treated based on etiology. There is no evidence of the affect of symptomatic treatment for cough in children

Levodropropizine for treating cough in adult and children: a meta-analysis of published studies.

BackgroundCough is one of the most common symptoms for which patients seek medical attention from primary care physicians and lung specialists. About 40% of the population at any one time report cough.Cough is associated with significantly impaired health-related quality of life.Levodropropizine is an effective and very well tolerated peripheral antitussive drug. We want to compare it to central cough suppressants efficacy (opioids and non-opioids) that may be associated with side effects limiting their use.MethodsAfter a comprehensive literature search, a meta-analysis of 7 clinical studies of levodropropizine vs. control, including a total of 1,178 patients, was performed with the aim to evaluate the overall comparative efficacy of levodropropizine in the pediatric and adult population.Three electronic databases and reference list were used to search for studies that assessed the efficacy of levodropropizine for treating cough in children and adults using as standardized efficacy parameters the cough frequency and severity, and number of night awakenings as outcome parameters.ResultsThe meta-analysis of all standardized efficacy parameters showed a highly statistically significant difference in the overall antitussive efficacy in favor of levodropropizine vs. control treatments (p = 0.0015).The heterogeneity test for the efficacy outcome was not statistically significant (p = 0.0534).Seven studies met out inclusion criteria. A meta-analysis of the eligible ones showed a statistically significant difference in the overall anti-tussive effect of levodropropizine versus control (p = 0.0015).ConclusionsThis analysis indicates that levodropropizine is an effective antitussive drug in children and adults, with statistically significant better overall efficacy outcomes vs. central antitussive drugs (codeine, cloperastine, dextromethorphan) in terms of reducing cough intensity and frequency, and nocturnal awakenings. This result further reinforces the favorable benefit/risk profile of levodropropizine in the management of cough. The efficacy of levodropropizine in the treatment of cough in children and adults is higher than that of the common centrally-acting anti-tussive.

Levodropropizine for treating cough in adult and children: a meta-analysis of published studies

Background: Cough is one of the most common symptoms for which patients seek medical attention from primary care physicians and lung specialists. About 40% of the population at any one time report cough. Cough is associated with significantly impaired health-related quality of life. Levodropropizine is an effective and very well tolerated peripheral antitussive drug. We want to compare it to central cough suppressants efficacy (opioids and non-opioids) that may be associated with side effects limiting their use.
 Methods: After a comprehensive literature search, a meta-analysis of 7 clinical studies of levodropropizine vs. control, including a total of 1,178 patients, was performed with the aim to evaluate the overall comparative efficacy of levodropropizine in the pediatric and adult population. Three electronic databases and reference list were used to search for studies that assessed the efficacy of levodropropizine for treating cough in children and adults using as standardized efficacy parameters the cough frequency and severity, and number of night awakenings as outcome parameters.
 Results: The meta-analysis of all standardized efficacy parameters showed a highly statistically significant difference in the overall antitussive efficacy in favor of levodropropizine vs. control treatments (p = 0.0015). The heterogeneity test for the efficacy outcome was not statistically significant (p = 0.0534). Seven studies met out inclusion criteria. A meta-analysis of the eligible ones showed a statistically significant difference in the overall anti-tussive effect of levodropropizine versus control (p = 0.0015).
 Conclusions: This analysis indicates that levodropropizine is an effective antitussive drug in children and adults, with statistically significant better overall efficacy outcomes vs. central antitussive drugs (codeine, cloperastine, dextromethorphan) in terms of reducing cough intensity and frequency, and nocturnal awakenings. This result further reinforces the favorable benefit/risk profile of levodropropizine in the management of cough. The efficacy of levodropropizine in the treatment of cough in children and adults is higher than that of the common centrally-acting anti-tussive.

Вибір препарату для лікування кашлю у дітей: доцільність, ефективність, безпечність, комплаєнс

Вибір препарату для лікування кашлю у дітей: доцільність, ефективність, безпечність, комплаєнс